MediPharm Labs Corp. LABS

MediPharm Labs Corp (MEDIF) reports record adjusted EBITDA and positive net income, driven by a 26% surge in international medical cannabis revenue.

Q2 2026 Adjusted EBITDA1 of $0.9M, the Company’s strongest quarterly performance since 20192Positive net income in Q2 2026, compared with a net loss of $3.8M in Q2 2025OPEX decreased 44% in Q2 2026 versus Q2 2025Net Revenue of $10.0M, an increase of 11% versus Q1 2026 with German revenue increasing 45% sequentially and 33% year over yearCash of $9.9M consistent with Q1 2026, and the Company remains virtually debt free, with outright ownership of two production facilities appraised at over $15MPo

TORONTO, Aug. 10, 2026 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs" or the "Company") a pharmaceutical company specialized in precision-based cannabinoids, is pleased to announce it will release its second quarter financial results for the three and six months ended June 30th, 2026, before markets open on Thursday, August 13th, 2026. MediPharm Labs executive management team will also host a conference call and webcast on August 13t

Results presented by the LiBBY study team at the Alzheimer’s Association International Conference (“AAIC”) demonstrated statistically significant improvements in agitation symptoms compared with placebo.The LiBBY study evaluated MediPharm Labs’ proprietary oral cannabinoid formulation, developed and supplied exclusively by MediPharm Labs for use in the trial. TORONTO, July 14, 2026 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) (“MediPharm”, “MediPharm Labs” or th

TORONTO, June 17, 2026 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) (“MediPharm”, “MediPharm Labs” or the “Company”), a pharmaceutical company specialized in precision-based cannabinoids, today announced the results of matters voted on at its annual and special meeting (the “Meeting”) of holders of common shares (“Shareholders”) held today. There were 389 Shareholders represented virtually or by proxy at the Meeting holding an aggregate of 130,357,074 common sha

Annual and Special Meeting to be held virtually on Wednesday, June 17, 2026 at 11:00 a.m. (Eastern Time).The Board of Directors recommends shareholders vote FOR all director nominees and resolutions, before the 11:00 a.m. (Eastern Time) deadline on Monday, June 15, 2026.Shareholders who have questions or need assistance voting their shares may contact TSX Trust Company at 1-866-600-5869 or [email protected]. TORONTO, May 28, 2026 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (

MediPharm Labs Corp (MEDIF) reports a return to positive adjusted EBITDA, strong international growth, and a robust balance sheet, despite facing domestic revenue headwinds.

MediPharm Labs (OTC:MEDIF) reported first-quarter financial results on Wednesday. The transcript from the company's first-quarter earnings call has been provided below. This transcript is brought to you by Benzinga APIs. For real-time access to our entire catalog, please visit https://www.benzinga.com/apis/ for a consultation. View the webcast at https://events.q4inc.com/attendee/116870256 Summary MediPharm Labs reported Q1 2026 revenue of CAD 9.0 million, a decrease from CAD 10.8 million in Q1

MediPharm Labs (TSX:LABS) held its first-quarter earnings conference call on Wednesday. Below is the complete transcript from the call. This transcript is brought to you by Benzinga APIs. For real-time access to our entire catalog, please visit https://www.benzinga.com/apis/ for a consultation. Access the full call at https://events.q4inc.com/attendee/116870256 Summary MediPharm Labs reported Q1 2026 revenue of $9.0 million, down from $10.8 million in Q1 2025, with a gross profit of $3.3 million

Q1 2026 Positive Adjusted EBITDA(1)Net Revenue of $9M with strong gross margins of 37%OPEX decreased 28% in Q1 2026 versus Q4 2025Company is virtually debt free, with a Q1 ending cash balance of $9.9 million and outright ownership of two licensed production facilitiesManagement to Host Conference Call / Webcast on May 13th, 2026, at 10:00 am ET TORONTO, May 13, 2026 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs" or the "Company"), a

On April 22, 2026, the U.S. Department of Justice and Drug Enforcement Administration’s final order rescheduling FDA-approved cannabis drug products and state-licensed medical cannabis from Schedule I to Schedule III of the Controlled Substances Act took effect.MediPharm Labs has already supplied product for over 10 active clinical trials, including a U.S. National Institutes of Health funded study, and has completed multiple API and clinical trial material shipments to the United States.MediPha

While the Canadian market navigates a landscape filled with uncertainties, particularly around energy supply disruptions and geopolitical tensions, investors are advised to maintain a balanced approach between growth and value sectors. Despite being considered somewhat outdated, penny stocks continue to offer intriguing opportunities for those willing to explore smaller or newer companies that may provide both affordability and growth potential. In this article, we will examine three notable...

MediPharm Labs Corp (MEDIF) reports 8% annual revenue growth and improved profitability, driven by a robust international medical cannabis segment.

FY 2025 revenue of $45.1 million, an increase of 8% over 2024International Medical Cannabis revenue increased 43% year-over-year and represented more than 50% of total revenueIncreased cash balance of $10.8 Million at the end of Q4, up $0.2 million from Q3 2025Company remains virtually debt-free, with outright ownership of two production facilitiesManagement to Host Conference Call / Webcast on March 30th, 2026, at 10:00 am ET TORONTO, March 30, 2026 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX

TORONTO, March 25, 2026 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs" or the "Company") a pharmaceutical company specialized in precision-based cannabinoids, is pleased to announce it will release its full year and fourth quarter financial results for the three and twelve months ended December 31st, 2025, before markets open on Monday, March 30th, 2026. MediPharm Labs executive management team will also host a conference call and we

MediPharm Labs (LABS.TO) on Monday announced that David Pidduck will be stepping down from his role

TORONTO, Nov. 14, 2025 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) (“MediPharm” or the “Company”), a pharmaceutical company specialized in precision-based cannabinoids, today announced that the Superior Court of Justice – Ontario (Commercial List) (the “Court”) has fully dismissed the statement of claim (CV-25-00742450-0000) (the “Claim”) issued by Apollo Technology Capital Corporation (“Apollo”), Nobul Technologies Inc. (“Nobul”), and Regan McGee (together wit

MediPharm Labs Corp (MEDIF) reports strong international revenue growth and innovative product launches, despite facing margin compression and market pressures.